Disc Medicine (IRON) Expected to Announce Earnings on Tuesday

Disc Medicine (NASDAQ:IRON) is expected to issue its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($1.52) per share for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 7:00 AM ET.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.41). On average, analysts expect Disc Medicine to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Disc Medicine Stock Up 0.6%

Shares of IRON traded up $0.51 on Tuesday, hitting $85.20. The company’s stock had a trading volume of 28,582 shares, compared to its average volume of 411,007. The company has a quick ratio of 32.11, a current ratio of 32.11 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of -19.06 and a beta of 0.79. Disc Medicine has a fifty-two week low of $30.82 and a fifty-two week high of $95.95. The firm’s fifty day moving average price is $69.57 and its 200-day moving average price is $58.62.

Insider Activity at Disc Medicine

In other news, Director Kevin Bitterman sold 70,000 shares of the business’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $88.91, for a total transaction of $6,223,700.00. Following the sale, the director owned 385,549 shares in the company, valued at approximately $34,279,161.59. The trade was a 15.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 218,046 shares of company stock worth $16,463,375. Insiders own 3.64% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IRON. Tower Research Capital LLC TRC boosted its position in shares of Disc Medicine by 383.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock valued at $211,000 after acquiring an additional 3,152 shares during the last quarter. First Trust Advisors LP purchased a new position in Disc Medicine during the 2nd quarter worth $543,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Disc Medicine by 22.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock worth $756,000 after purchasing an additional 2,807 shares during the period. Invesco Ltd. increased its holdings in Disc Medicine by 21.6% during the 2nd quarter. Invesco Ltd. now owns 16,817 shares of the company’s stock worth $891,000 after purchasing an additional 2,983 shares during the period. Finally, Legal & General Group Plc boosted its position in Disc Medicine by 18.0% during the 2nd quarter. Legal & General Group Plc now owns 24,097 shares of the company’s stock valued at $1,276,000 after acquiring an additional 3,682 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, October 8th. National Bankshares set a $153.00 price target on Disc Medicine in a research report on Friday, October 17th. Morgan Stanley boosted their price objective on Disc Medicine from $90.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Wedbush increased their price objective on Disc Medicine from $90.00 to $110.00 and gave the stock an “outperform” rating in a research note on Friday, October 17th. Finally, Truist Financial initiated coverage on Disc Medicine in a research report on Monday, July 21st. They set a “buy” rating and a $86.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and an average price target of $116.30.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.